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BEVACIZUMAB VERSUS RANIBIZUMAB FOR AGE-RELATED MACULAR
DEGENERATION (AMD): A BUDGET IMPACT ANALYSIS
Zimmermann I, Schneiders RE, Mosca M, Alexandre RF, do Nascimento Jr JM, Gadelha
CA
Ministry of Health, Brasília, DF, Brazil
OBJECTIVES: The use of intravitreal injection of vascular endothelial growth factor
inhibitors is an effective treatment for AMD and trials have showed similar clinical
effects of bevacizumab and ranibizumab. The aim of this study was to estimate the
budget impact for Brazilian Ministry of Health (MoH) recommending ranibizumab
instead of bevacizumab for AMD.METHODS:We did a deterministic budget impact
analysis, with the MoH perspective, comparing the use of ranibizumab and bevaci-
zumab for wet AMD. The target population was estimated by extrapolating epide-
miologic data to the Brazilian population. Data about dosage, administration and
fractioning were extracted from literature. Prices were obtained with the Brazilian
regulatory agency, applying potential discounting benefits. This analysis did not
consider the cost of the fractioning process because it will be assumed by the states
and not by the MoH. RESULTS: The considered price of the ranibizumab vial was
US$ 962.86 (fractioning is not an option). In contrast, a 4 mL vial of bevacizumab
would cost US$ 410.86 (US$ 5.14 each 0.05 mL dose, resulting in 80 doses/vial).
Therefore, the expenses of one year on ranibizumab would be about US$ 11,554.37
and about US$ 61.63 for bevacizumab (12 injections for both). Thus, the use of
ranibizumab instead of bevacizumab for treating 467,600 people would be related
with a US$ 5,374,007,960.48 budget impact. The sensitivity analyses also demon-
strated a budget impact of US$ 3,097,416,007.65 and US$ 5,287,555,101.51 (1 dose/
vial and 20 doses/vial, respectively). CONCLUSIONS: Although not a label indica-
tion, bevacizumab has been widely adopted in clinical practice. As presented
above, even with inefficient fractioning methods, the use of bevacizumab would
bring substantial savings to MoH resources. Even the need of preserving the steril-
ity of the solution being a real-world worry, stability studies have showed the
maintenance of the solution characteristics through adequate handling and stor-
age.
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COST-OF-ILLNESS OF CHRONIC LYMPHOEDEMA PATIENTS IN HAMBURG AND
SUBURBAN REGION
Purwins S1, Dietz D1, Blome C2, Heyer K1, Herberger K1, Augustin M1
1University Clinics of Hamburg, Hamburg, Germany, 2University Medical Center Hamburg,
Hamburg, Germany
OBJECTIVES: Chronic lymphedema is of particular interest from the socioeco-
nomic point of view, since it is accompanied with high costs, disease burden and
permanent need of medical treatment. The economic and social impact can in-
crease if complications such as erysipelas and ulcers develop. Therefore, cost-of-
illness of patients with lymphoedema or lipoedema should be known. METHODS:
Patients with chronic primary or secondary lymph- or lipoedema of upper or lower
limbs, with at most 6 months of disease duration, were enrolled in an observa-
tional, cross-sectional study in Hamburg and surroundings (population of approx-
imately 4 Mio inhabitants, 90% of which are insured in the statutory health insur-
ance (SHI) and 10% in private insurance). Standardized clinical examinations and
patient interviews were carried out. The oedemas were documented via digital
photography as well as further available patient data. Resource utilizations were
collected. From the societal perspective direct medical, non - medical and indirect
costs were computed. RESULTS: A total of 348 patients were enrolled and inter-
viewed. 90.8% of them were female and had a mean age of 57.3 14.5 years. Mean
annual costs per lymphoedema were €8121. These costs consisted of 58% direct
(€4708) and 42% indirect (€3413) costs. The SHI accounted for about €5552 expenses
and the patient €494.20 out-of-pocket costs. Conducted subgroup analyses on (a)
arm vs leg oedema and (b) primary vs secondary vs lipo-lymphoedema did not
show significant differences in costs. The main costs drivers in this study were
medical treatment and disability costs. CONCLUSIONS: The treatment of patients
with chronic lymphoedema is associated with high direct and indirect costs.
PSS7
C-REALITY (CANADIAN BURDEN OF DIABETIC MACULAR EDEMA
OBSERVATIONAL STUDY): 6-MONTH FINDINGS
Barbeau M1, Gonder J2, Walker V3, Zaour N1, Hartje J4, Li R1
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2St. Joseph’s Health Care, London,
ON, Canada, 3OptumInsight, Burlington, ON, Canada, 4OptumInsight, Eden Prairie, MN, USA
OBJECTIVES:To characterize the economic and societal burden of Diabetic Macular
Edema (DME) in Canada. METHODS: Patients with clinically significant macular
edema (CSME) were enrolled by ophthalmologists and retinal specialists across
Canada. Patients were followed over a 6-month period to combine prospective data
collected during monthly telephone interviews and at sites at months 0, 3 and 6.
Visual acuity (VA) was measured and DME-related health care resource informa-
tion was collected. Patient health-related quality of life (HRQOL) was measured
using the National Eye Institute Visual Functioning Questionnaire (VFQ-25), and
the EuroQol Five Dimensions (EQ-5D). RESULTS: A total of 145 patients [mean age
63.7 years (range: 30-86 yrs); 52% male; 81% Type 2 diabetes; mean duration of
diabetes 18 years (range: 1-62 yrs); 72% bilateral CSME] were enrolled from 16 sites
across 6 provinces in Canada. At baseline, the mean VA was 20/60 (range: 20/20-
20/800) across all eyes diagnosed with CSME (249 eyes). Sixty-three percent of pa-
tients had VA severity in the eye diagnosed with DME (worse seeing eye if both eyes
diagnosed) of normal/mild vision loss (VA 20/10 to  20/80), 10% moderate vision
loss (VA 20/80 to 20/200), and 26% severe vision loss/nearly blind (VA 20/200).
At month 6, the mean VFQ-25 composite score was 79.6, the mean EQ-5D utility
score was 0.78, and the EQ visual analogue scale (VAS) score was 71.0. The average
6-month DME-related cost per patient was $2,092 across all patients (95% confi-
dence interval: $1,694 to $2,490). The cost was $1,776 for patients with normal/mild
vision loss, $1,845 for patients with moderate vision loss, and $3,007 for patients
with severe vision loss/nearly blind. CONCLUSIONS: DME is associated with limi-
tations in functional ability and quality of life. In addition, the DME-related cost is
substantial to the Canadian health care system.
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NON-INTERVENTIONAL STUDY ON THE BURDEN OF ILLNESS IN DIABETIC
MACULAR EDEMA (DME) IN BELGIUM
Nivelle E1, Caekelbergh K1, Moeremans K1, Gerlier L2, Drieskens S3, Van dijck P4
1IMS Health HEOR, Vilvoorde, Belgium, 2IMS Health, Vilvoorde, Belgium, 3Panacea Officinalis,
Antwerp, Belgium, 4N.V. Novartis Pharma S.A., Vilvoorde, Belgium
OBJECTIVES: To study real-life patient characteristics, treatment patterns and
costs associated with DME and visual acuity (VA) level. METHODS: The study
aimed to recruit 100 patients distributed evenly over 4 categories defined by last
measured VA. 1-year retrospective data were collected from medical records. An-
nual direct costs were calculated from resource use in medical records and official
unit costs (€ 2011). Self-reported economic burden was collected via Short Form
Health and Labour Questionnaire (SF-HLQ). Indirect costs (€ 2011) included per-
sonal expenses and caregiver burden (SF-HLQ). RESULTS: Thirteen Belgian oph-
thalmologists recruited 32, 12, 14 and 6 DME patients for VA categories 20/50,
20/63-20/160, 20/200-20/400 and 20/400 respectively. VA was stable during the
study in 86% of patients. Recruitment for lower VA categories was difficult due to
long-term vision conservation with current treatments, lack of differentiation be-
tween lowest categories in medical records and discontinuation of ophthalmolo-
gist care in lowest categories. 75% of patients had bilateral DME. 68% were treated
for DME during the study, of which 60% in both eyes. 50% received photocoagula-
tion, 33% intravitreal drugs. Less than 4% of patients had paid work; 17% received
disability replacement income. Total direct medical costs in patients receiving
active treatment ranged from €960 (lowest VA) to €3,058. 59% of direct costs were
due to monitoring and vision support, 39% to DME treatment. Indirect cost trends
were less intuitive due to small samples and large variations. Annual costs grouped
by 2 highest and 2 lowest VA levels, were respectively €114 and €312 for visual aids,
€407 and €3,854 for home care. CONCLUSIONS: The majority of DME patients had
bilateral disease. Except for the lowest VA, direct medical costs increased with VA
decrease. Indirect costs were substantially higher at lower VA levels. Low sample
sizes in some categories did not allow statistical analysis of cost differences.
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COST OF BLINDNESS AND VISUAL IMPAIRMENT IN SLOVAKIA
Psenkova M1, Mackovicova S2, Ondrusova M3, Szilagyiova P4
1Pharm-In, Bratislava, Slovak Republic, 2Pharm-In, spol. s r.o., Bratislava, Slovak Republic,
3Pharm-In, Ltd., Bratislava, Slovak Republic, 4Pfizer Luxembourg SARL, Bratislava, Slovak
Republic
OBJECTIVES: To measure the burden of the disease and provide a basis for the
health care policy decisions. METHODS: The analysis was performed based on the
several data sources. Data on prevalence of bilateral blindness and visual impair-
ment were obtained from the official Annual Report on the Ophthalmic Clinics
Activities. Cost analysis was performed from the Health and Social Insurance per-
spective and reflects the real costs of health care payers in 2010. Information on
health care and social expenditure were obtained from State Health and Social
Insurance Funds. As detailed data on expenditures were not always available in a
necessary structure, the missing data were collected in the retrospective patient
survey. Both direct and indirect costs were evaluated and divided by the cost type
and level of visual impairment. For the estimation of indirect costs Capital method
was used. Patient survey was conducted on randomly collected geographically
homogeneous sample of 89 respondents from all over Slovakia. RESULTS:A total of
17 201 persons with bilateral blindness or visual impairment were identified in
2010. Total yearly expenditures were 63 677 300 €. Direct costs counted only for 7%
(4 468 112 €) of total costs and the most of them were caused by hospitalisations (4
001 539 €) and medical devices (307 739 €). The indirect costs counted for 59 209 188
€. The highest share represented loss of productivity (69%), followed by disability
pensions (17%) and compensation of medical devices (14%). CONCLUSIONS: The
evidence of cost-effectiveness must be demonstrated in order to get reimburse-
ment in Slovakia. According the Slovak guidelines indirect costs are accepted only
in exceptional cases. Indirect costs of blindness and visual impairment count more
than two thirds of total costs and therefore should be considered in health care
policy evaluations.
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ECONOMICAL BURDEN OF SEVERE VISUAL IMPAIRMENT AND BLINDNESS – A
SYSTEMATIC REVIEW
Köberlein J1, Beifus K1, Finger R2
1University of Wuppertal, Wuppertal, Germany, 2University of Bonn, Bonn, Germany
OBJECTIVES: Visual impairment and blindness pose a significant burden in terms
of costs on the affected individual as well as society. In addition to a significant loss
of quality of life associated with these impairments, a loss of independence leading
to increased dependence on caretakers and inability to engage in income generat-
ing activities add to the overall societal cost. As there are currently next to no data
capturing this impact available for Germany we conducted a systematic review of
the literature to estimate the costs of visual impairment and blindness for Ger-
many and close this gap. METHODS: A systematic literature search of the main
medical and economic information databases was conducted from January-April
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2012. Supplementary material was identified by a manual examination of litera-
ture. Studies published between 1998 and 2011 were selected using predefined
criteria. Quality of the articles was rated by two independent investigators. Avail-
able data related to resource utilization and costs were extracted and cost units
calculated for Germany. RESULTS: A total of 66 articles were identified. After the
first abstract screening 24 full-text articles were identified as relevant. Finally, after
full-text screening, 10 articles could be included. The majority of studies focused on
the societal economic burden of both impairments. Indirect costs were highest
amongst all cost categories due to productivity loss. Only two identified articles
reported data for Germany. Out of these, one European study transferred survey
data from abroad to the German system and another article reported costs for
specific ophthalmological diseases. CONCLUSIONS: There is a dearth of literature
assessing the economic impact of visual impairment and blindness in Germany
indicating a need for research to fill this gap. Therefore, in a second step, we will
conduct a cost-of-illness study using a bottom-up approach to explore cost units in
detail, as well as their determinants and intangible effects for Germany.
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ECONOMIC EVALUATION OF BIOLOGIC TREATMENTS FOR MODERATE TO
SEVERE PSORIASIS IN ITALY
Marcellusi A1, Gitto L1, Giannantoni P1, Attinà G2, Sundaram M3, Mennini FS1
1University of Rome, Rome, Italy, 2Abbott Italy, Latina, Italy, 3QualityMetric Health Outcomes
Solutions, Lincoln, RI, USA
OBJECTIVES: Psoriasis is a chronic disease that impacts significantly on patients’
quality of life (QoL). Biological drugs interfere in the immunologic process that
triggers and supports psoriasis and, therefore, prove effective in its treatment. The
aim of this study was to perform a cost-utility analysis (CUA) comparing biologic
treatments (adalimumab, etanercept, infliximab, and ustekinumab) in Italy.
METHODS: A decision tree model previously applied to the UK was adapted for
Italy using resource and cost data from the Italian Ministry of Health (Ministero
della Salute). Clinical efficacy in the treatment of moderate to severe psoriasis was
determined by the Psoriasis Area Criteria and Severity Index (PASI). Relative effi-
cacy of biologic treatments was based on a network meta-analysis of clinical trials.
A different level of utility is associated with each level of PASI response. Costs
included hospitalization, drug acquisition, administration, and monitoring over a
10-year time horizon. Incremental cost-effectiveness ratios (ICERs) compared with
supportive care (no systemic therapy) were expressed as euros/quality-adjusted
life year (QALY). One-way sensitivity analyses, where key parameters were
changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost effective
compared to supportive care (ICER: €52,583), followed by ustekinumab 90 mg (ICER:
€52,846), ustekinumab 45 mg (ICER: €54,997), infliximab (ICER: €56,141), etanercept
50 mg BIW (ICER: €77,611), and etanercept 25 mg BIW (ICER: €78,194). The ICER for
ustekinumab 90 mg, ustekinumab 45mg, and infliximab compared to adalimumab
were €57,052, €140,445, and €86,794, respectively. Adalimumab remained the most
cost-effective over the vast majority of the one-way sensitivity analyses.
CONCLUSIONS: The analysis demonstrated that adalimumab is the most cost-
effective biologic for the treatment of patients affected by moderate to severe
psoriasis.
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NEPAFENAC FOR THE REDUCTION IN RISK OF POST-OPERATIVE MACULAR
OEDEMA ASSOCIATED WITH CATARACT SURGERY IN DIABETIC PATIENTS: A
COST-EFFECTIVENESS ESTIMATION FOR SCOTLAND
Jackson D1, Fisher R2, Latif F3
1Alcon Laboratories, Hünenberg, Switzerland, 2Alcon Laboratories, Camberley, UK, 3Double Helix
Consulting, London, UK
OBJECTIVES: Treatment strategies for the prevention of macular oedema (MO) in
diabetic patients include the postoperative use of steroids with and without anti-
biotics. However, measured with optimal coherence tomography (OCT), between
14% and 22% of diabetic patients still experience postoperative MO, with 3.05%
developing clinically significant MO (CSMO). Nepafenac has recently been granted
approval in Scotland for the licensed indication of reduction in risk of postopera-
tive MO associated with cataract surgery in diabetic patients. The primary objective
was to therefore estimate the incremental cost-effectiveness ratio (ICER) of
Nepafenac compared to the identified standard practice of Prednisolone Acetate
Ophthalmic Suspension (PAOS). METHODS: An Excel-based cost-utility model was
developed with a 90-day time horizon (base-case). An appropriate comparator was
established via consultation with an expert advisory-board comprised of 3 oph-
thalmologists currently practising in Scotland. Effectiveness data were derived
from the pivotal study, C-07-43, whereby the primary outcome demonstrated that
a significantly smaller percentage of patients in the Nepafenac group developed
MO relative to patients in the vehicle group (3.2% vs 16.7%; p0.001). The difference
at 90 days was converted to a RR of MO  0.19. Costs comprised drug acquisition
and outpatient costs, the latter including physician visits and OCT, derived from
ISD Scotland and the BNF 63. Importantly, costs were only associated with those
patients with clinically diagnosed MO. In terms of utilities, an algorithm associat-
ing logMAR visual acuity (VA) with health-related utility estimated with TTO was
used to populate the model. RESULTS: Nepafenac had an ICER of £6,552 per QALY
compared to PAOS in the base-case scenario. CONCLUSIONS: Nepafenac is highly
cost-effective compared to Prednisolone Acetate, and with a concomitant low bud-
get impact (estimated annual maximum of £110,500), should be considered as the
primary treatment for reduction in risk of postoperative MO associated with cata-
ract surgery in diabetic patients.
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COST-EFFECTIVENESS OF SPECIALIZED TREATMENT BASED ON COGNITIVE
BEHAVIOURAL THERAPY VERSUS USUAL CARE FOR TINNITUS
Maes IH1, Cima RF2, Anteunis LJ1, Baguley DM3, El Refaie A4, Scheijen DJ5, Vlaeyen JJ6,
Joore MA7
1Maastricht University Medical Centre, Maastricht, The Netherlands, 2Maastricht University,
Maastricht, The Netherlands, 3University of Cambridge, Cambridge, UK, 4University of Bristol,
Bristol, UK, 5Adelante Audiologie & Communicatie, Hoensbroek, The Netherlands, 6University of
Leuve, Leuven, Belgium, 7MUMC, Maastricht, The Netherlands
OBJECTIVES: Up to 21% of adults will develop tinnitus, manifesting the perception
of a noxious disabling internal sound. Many different treatments are offered, but
evidence on their effectiveness and cost-effectiveness is scarce or absent. Recently,
the effectiveness of a specialised treatment of tinnitus based on cognitive behav-
ioural therapy was demonstrated (Cima et al., 2012). The present study evaluates
the cost-effectiveness of this treatment compared to care as usual, in an audiolog-
ical centre. METHODS: An economic evaluation was carried out alongside a ran-
domized controlled clinical trial. The economic evaluation was conducted from a
societal perspective, using a one-year time horizon. The incremental cost effective-
ness ratio (iCER) was calculated by dividing the difference in costs by the difference
in Quality Adjusted Life Years (QALYs) based on the HUI Mark III. Non-parametric
bootstrapping and sensitivity analyses were used to asses the uncertainty in costs
and effects. Sensitivity analysis included a complete cases analysis and analysis on
data were missing values on the HUI mark III were imputed based on a mixed
regression model from the clinical effectiveness analysis. RESULTS: Compared to
patients receiving usual care, patients who received specialised care gained on
average 0.015 QALYs (BCI:-0.028-0.055) The incremental costs from a societal per-
spective are €286 (BCI:-€828-€1427). The incremental cost per QALY from a societal
perspective amounted to €19,688. The probability that SC is cost-effective from a
societal perspective is 57% for a willingness to pay for a QALY of €35,000.
CONCLUSIONS: Specialised multidisciplinary tinnitus based on cognitive behav-
ioural therapy is cost-effective as compared to usual care. Although uncertainty
surrounding the incremental costs and effects is considerable, sensitivity analysis
indicated that cost-effectiveness results were robust.
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COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF
MODERATE TO SEVERE PSORIASIS IN GERMANY
Betts K1, Yan Y2, Sundaram M3, Hengst N4, Wolff M4, Bensimon AG1
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Abbott
Laboratories, Abbott Park, IL, USA, 4Abbott GmbH & Co. KG, Ludwigshafen, Germany
OBJECTIVES: Etanercept, infliximab, ustekinumab, and adalimumab have been
granted marketing authorization for the treatment of moderate-to-severe psoriasis
in Germany. The objective of this study is to evaluate cost-effectiveness of biologic
treatments from the German Social Health Insurance (SHI) perspective.METHODS:
A simple decision model was constructed to assess the cost-effectiveness of bio-
logics compared to supportive care for the treatment of moderate-to-severe psori-
asis over a one-year time horizon. Clinical efficacy was based on the relative prob-
abilities of achieving PASI75, and PASI 90 response obtained via a network meta-
analysis. Weight-based dosing was assumed for infliximab and ustekinumab.
Costs were assessed in terms of 2012 euros, and included drug acquisition, admin-
istration, laboratory tests, clinic visits, and hospitalization costs. Cost-effective-
ness from payer perspective was assessed as the cost-per-PASI75 response and
cost-per-PASI90 response compared with supportive care (no systemic therapy)
over a one-year time horizon. One-way sensitivity analyses, where key parameters
were changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost-effective
compared to supportive care (€25,378 per PASI75 responder and €46,870 per PASI90
responder), followed by infliximab (€30,719 per PASI75 responder and €47,300 per
PASI90 responder), ustekinumab (€31,953 per PASI75 responder, and €57,852 per
PASI90 responder), etanercept 50mg BIW (€43,049 per PASI75 responder and
€101,306 per PASI90 responder), and etanercept 25 mg BIW (€43,156 per PASI75
responder and €111,369 per PASI90 responder). The incremental cost per PASI 75
responder gained and the incremental cost per PASI 90 for infliximab compared to
adalimumab were €51,812 and €48,112, and €87,942 and €106,911 respectively for
ustekinumab. Adalimumab remained the most cost-effective over the vast major-
ity of the one-way sensitivity analyses. CONCLUSIONS: This study found that ada-
limumab is the most cost-effective biologic treatment for moderate to severe pso-
riasis from the German SHI perspective.
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A NEW INSIGHT INTO COST-EFFECTIVENESS ANALYSES IN ATOPIC
DERMATITIS: THE TACROLIMUS 0.1% OINTMENT VERSUS CICLOSPORIN
COMPARISON
Almeida J1, Vandewalle B1, Silva MJ2, Félix J1
1Exigo Consultores, Alhos Vedros, Setúbal, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon,
Portugal
OBJECTIVES: Atopic dermatitis (AD) affects more than 15% of the population car-
rying a heavy burden in developed countries and leading to significant losses in
patients’ quality of life, especially in children. Although no cure has yet been found
for AD, novel drugs such as tacrolimus have been released in recent years. There-
fore this study aimed to perform a cost-effectiveness analysis comparing tacroli-
mus 0.1% ointment with ciclosporin 100mg for the treatment of moderate to severe
AD from the Portuguese societal perspective. METHODS: An individual simulation
event process was designed to mimic the natural course and treatment of the
disease, including relapse and maintenance phases. Time to remission and time to
relapse were simulated according to data from a 6-week randomised trial between
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